Last reviewed · How we verify

VI — Competitive Intelligence Brief

VI (VI) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant zoster vaccine. Area: Immunology / Infectious Disease.

marketed Recombinant zoster vaccine Varicella zoster virus glycoprotein E (gE) Immunology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

VI (VI) — GlaxoSmithKline. VI is a varicella zoster virus vaccine that stimulates immune response to prevent herpes zoster (shingles) infection.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
VI TARGET VI GlaxoSmithKline marketed Recombinant zoster vaccine Varicella zoster virus glycoprotein E (gE)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant zoster vaccine class)

  1. GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). VI — Competitive Intelligence Brief. https://druglandscape.com/ci/vi. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: